Progress in therapeutics and biotechnologies leveraging new insights in our understanding of cancer biology and progression have had an underwhelming clinical significance thus far. A key challenge arising from the creation of nanomedicines consolidating multiple desirable functionalities into a 'all-in-one' platform is that the layering of functionalities into a single agent introduces novel complexities that significantly impede clinical translation. An alternative design approach seeks to exploit intrinsically multi-functional building block to assemble nanomedicines from the bottom-up, yielding agents with a multiplicity of radiologic, pharmacologic, and therapeutic properties derived from a single constituent. Herein are highlighted recent developments in the formulation, multi-modal imaging, and targeting of an exemplary 'one-for-all' nanomaterial-the Pyropheophorbide Porphysome-treated from a hitherto unexplored clinical design and development perspective.
Copyright © 2016 Elsevier Ltd. All rights reserved.